Publications by authors named "Jennifer Sugg"

Claim this Profile
H
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.
Nima Sharifi, Arun A Azad, Mona Patel, Jason W D Hearn, Michele Wozniak, Jennifer Sugg

Cell Rep Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Jennifer Sugg

N Engl J Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Jennifer Sugg

Future Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Jennifer Sugg

J Urol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, Jennifer Sugg

Future Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Jennifer Sugg

Prostate Cancer Prostatic Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Anthony M Joshua, Andrew Armstrong, Megan Crumbaker, Howard I Scher, Johann de Bono, Jennifer Sugg

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Jennifer Sugg

Prostate Cancer Prostatic Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, Jennifer Sugg

Eur J Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer.
Filip Janku, Patricia LoRusso, Aaron S Mansfield, Rita Nanda, Alexander Spira, Jennifer Sugg

Invest New Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Stephen J Freedland, Ugo De Giorgi, Martin Gleave, Brad Rosbrook, Qi Shen, Jennifer Sugg

BMJ Open· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Taro Iguchi, Go Kimura, Satoshi Fukasawa, Hiroyoshi Suzuki, Hiroji Uemura, Jennifer Sugg

Int J Urol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Andrew Wardley, Javier Cortes, Louise Provencher, Kathy Miller, A Jo Chien, Jennifer Sugg

Breast Cancer Res Treat· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Fred Saad, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Jennifer Sugg

Eur Urol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Cora N Sternberg, Karim Fizazi, Fred Saad, Neal D Shore, Ugo De Giorgi, Jennifer Sugg

N Engl J Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Andrew J Armstrong, Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg

JAMA Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Jennifer Sugg

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh,

Diabetes Care· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
William T Cefalu, Lawrence A Leiter, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg

Diabetes Care· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.
Sarah Bujac, Angelo Del Parigi, Jennifer Sugg, Susan Grandy, Tom Liptrot

Diabetes Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study.
Björn W Karlson, Mikael Dellborg, Lars Gullestad, Jan Aberg, Jennifer Sugg

Cardiology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg

J Am Geriatr Soc· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.
Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde

Diabetes Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary tract infections in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis